Adjuvant Treatment With Serplulimab，Trastuzumab & SOX in the HER-2

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05070598` - Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer	Phase 2
Active, not recruiting	`NCT04082364` - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer	Phase 2/Phase 3
Completed	`NCT03330561` - PRS-343 in HER2-Positive Solid Tumors	Phase 1
Recruiting	`NCT05619016` - [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors	Phase 2
Not yet recruiting	`NCT05586061` - First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer	Phase 2
Active, not recruiting	`NCT05190445` - Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma	Phase 2
Recruiting	`NCT05982834` - Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC	Phase 1/Phase 2
Not yet recruiting	`NCT05313906` - RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer	Phase 2
Recruiting	`NCT06328738` - ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer	Phase 1
Recruiting	`NCT04520295` - ctDNA Screening in Advanced HER2 Positive Gastric Cancer
Recruiting	`NCT04319757` - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors	Phase 1
Withdrawn	`NCT04464967` - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers	Phase 1/Phase 2
Recruiting	`NCT06253650` - Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease	Phase 2
Recruiting	`NCT05955833` - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study	Phase 1
Not yet recruiting	`NCT06414733` - Vaccine Therapy in Treating Patients With Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT05555251` - BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	Phase 1/Phase 2
Withdrawn	`NCT04602117` - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer	Phase 1
Recruiting	`NCT05514717` - A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2	Phase 1
Terminated	`NCT05091528` - A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers	Phase 1/Phase 2
Recruiting	`NCT05715931` - Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma	Phase 2

NCT number	NCT06439550
Study type	Interventional
Source	The First Affiliated Hospital of Zhengzhou University
Contact	Feng Wang
Phone	13938244776
Email	fengw010@163.com
Status	Not yet recruiting
Phase	Phase 2
Start date	July 15, 2024
Completion date	December 31, 2026

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms